AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug

Positive phase 3 trial result in unresectable liver cancer for an AstraZeneca drug. The outcome materially strengthens the commercial outlook and pipeline value for one of AstraZeneca's key growth drivers in a historically hard-to-treat indication and is likely to be positive for the stock and revenue trajectory.

Analysis

Positive phase 3 trial result in unresectable liver cancer for an AstraZeneca drug. The outcome materially strengthens the commercial outlook and pipeline value for one of AstraZeneca's key growth drivers in a historically hard-to-treat indication and is likely to be positive for the stock and revenue trajectory.